Evaluation of osteopontin as serum tumor marker for pancreatic cancer

Objective To evaluate the effect of osteopontin (OPN) as serum tumor marker on the diagnosis of pancreatic cancer.Methods Used ROC(receiver-operating characteristics)curve methods to assay the serum content of OPN,CA19-9 and CA242 in 46 patients of the pancreatic cancer,18 patients of the chronic pancreatitis detected by enzyme-linked immunosorbent assay (ELISA),and analyzed the results with statistics methods.Results The serum levels of OPN,CA19-9 and CA242 in pancreatic cancer are all higher than in chronic pancreatitis respectively (P0.001).To treat the measure results of four serum tumor markers with ROC curve methods,The AUC (area under curve) of OPN,CA19-9 and CA242 are 0.788,0.808 and 0.737,respectively.Subgroup analysis indicated that the OPN and CA19-9 levels for patients with resectable pancreatic cancer were lower than those for patients with unresectable pancreatic cancer (P0.001).Conclusion In diagnosis of pancreatic cancer,the clinical value of OPN is available.And the combination test of CA19-9 and OPN have clinical value to evaluate if the pancreatic cancer can be resected before operation.